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ABSTRACT 
Osteosarcoma is the most common primary malignant tumour of bone apart from 
myeloma. Many investigators are searching for prognostic factors to monitor the 
response of tumours to chemotherapy. Current studies focus on evaluating the 
reliability of P-glycoprotein expression using immunohistochemistry data. However, 
its association with response to chemotherapy is controversial since P-glycoprotein 
immunohistochemistry may only help to detect multidrug resistance in highly 
resistant tumours. Baldini and his co-workers developed the adriamycin binding assay 
which is a clinical assay and enables detection of low levels of resistance in tumour 
cell cultures. In this study, the applicability of P-glycoprotein immunohistochemistry 
and that of the adriamycin binding assay to predict tumour necrosis were compared. 
W e found that 46.15% of osteosarcoma samples studied had intrinsic adriamycin 
resistance as revealed by the adriamycin binding assay. However, P-glycoprotein 
expression was low in these samples. P-glycoprotein expression was elevated after 
chemotherapy, which may be the result of increased rate of synthesis. Pre-
chemotherapy adriamycin binding assay results correlate at a statistically significant 
value (p=0.042) with tumour necrosis. Post-chemotherapy adriamycin binding assay 
results and P-glycoprotein expression did not have a statistically significant 
correlation with tumour necrosis. Moreover, the correlation between adriamycin 
sensitivity and P-glycoprotein expression in our study was not statistically significant. 
In our osteosarcoma samples, P-glycoprotein expression is not the main reason for 
drug resistance as suggested by the adriamycin binding assay. Alternative mechanisms 
for drug resistance have been demonstrated. Adriamycin is known to impose growth 
inhibition on cancer cells. However, its effect on the activities of antioxidative 
enzymes is controversial. W e postulate that intracellular antioxidants might play a role 
in modulating drug response in osteosarcoma cells. Therefore, we extended our study 
using an in vitro model to investigate the effect of adriamycin on the proliferation rate 
and the activities of two critical antioxidative enzymes, catalase and glutathione 
ii 
peroxidase, in an osteosarcoma cell line. In addition, the adriamycin binding assay 
and P-glycoprotein immunohistochemistry were used to monitor the change of drug 
sensitivity during drug treatment in this model. 
Our in vitro study showed that after adriamycin treatment up to 40ngy'ml, the 
osteosarcoma cells developed adriamycin resistance, yet P-glycoprotein expression 
was not induced. The proliferation rate and the activities of antioxidative enzymes 
were all suppressed after incubating the cells with sub-concentration of adriamycin. 
The decrease in proliferation rate and antioxidative enzymes activities was postulated 
to be due to an inhibition by excess superoxide ions generated by adriamycin through 
quinone reduction. 
In this study, we have clearly demonstrated that pre-chemotherapy adriamycin binding 
assay is critical for screening out patients who are intrinsically drug resistant. W e also 
find that P-glycoprotein overexpression and enhanced activities of antioxidative 
enzymes may not be the rasons for adriamycin resistance. Further studies on other 
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According to the World Health Organization, osteosarcoma is defined as "a malignant 
tumour characterized by the direct formation of bone or osteoid by the tumour cells” 
(Schajowicz, 1993). It is the most common primary malignant tumour of bone apart 
from myeloma (Figure 1.1.). Osteosarcoma can be divided into two fundamental 
groups, namely the central (medullary) and the surface (peripheral) osteosarcomas. 
Intracortical osteosarcomas are extremely rare (Table 1.1.). 
1.1.1. Incidence 
The annual incidence of osteosarcoma in Chinese population is 0.23 cases per 
100,000 people (Bovill etal., 1975). In Hong Kong, its incidence is approximately 0.1 
per 100,000. In 1992, 41 males and 20 females were newly diagnosed with 
osteosarcoma. 16 male and 10 female patients died of the disease (Hospital Authority, 
1996). In the Prince of Wales Hospital about 10 new cases of osteosarcoma are 
diagnosed each year. 
The specific cause of osteosarcoma is not known. Evidence suggests that 
osteosarcoma can run in families. Associations with other diseases (many of which 
are hereditary) and recent advances in recombinant D N A technology have identified 
genes that indicate an increased risk. The gene involved in familial retinoblastoma 
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Figure 1.1. Osteosarcoma of the lower metaphysis of femur in 
a 13 years old male. The tumour extended into the 
epiphysis with periosteal new bone formation 
(Schajowicz, 1994). 
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Central QAedullaiy) Osteosarcoma Surface (Peripheral) Osteosarcoma 
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Conventional Central Osteosarcoma Parosteal (Juxtacortical) Osteosarcoma 
Telangiectatic Osteosarcoma Periosteal Osteosarcoma 
Intraosseous Well-DifFerentiated High-Grade Surface Osteosarcoma 
Osteosarcoma 
Round-Cell Osteosarcoma 
Table 1.1. Classification of osteosarcoma (Schajowicz, 1993). 
Osteosarcoma occurs most frequently in on bone surface 
or in the medullary. Intramedullary osteosarcomas are rare. 
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1.1.2. Age and Sex Distribution 
Osteosarcoma can occur at any age, although it mainly affects children. Most patients 
present with osteosarcoma during the first two decades of life, and patients between 
10 and 20 are by far the most commonly affected (Wilimas et cd., 1977). The mean 
age of patients is 24.9 in males and 24.6 in females, whereas the median is 18 for 
males and 17 for females. These figures all point to adolescence, during which a 
sudden burst of skeletal growth occurs, when the appearance of osteosarcoma is most 
likely (Dix et al., 1983). Males are affected slightly more frequently than females. 
Data from the Memorial Sloan-Kettering Cancer Center in the N e w York City show 
that the proportion of male to female patients is 1.3:1. This can be accounted by the 
longer period of skeletal growth and the additional volume of bone produced in the 
male. 
1.1.3. Clinical Features 
The rate of tumour growth, degree of bone destruction and the severity of symptoms 
vary greatly among osteosarcoma patients. The earliest symptom is pain in the 
involved bone. The pain often irradiates to a neighbouring joint, which begins 
insidiously and intermittently. The pain then becomes severe and constant and could 
not be relieved by rest, immobilization, or ordinary analgesics. A palpable mass 
slowly develops, hindering joint motion. Swelling is minimal at first but becomes 
more prominent. The skin overlying the tumour is often shiny and stretched, with 
superficial veins showing prominence and dilatation. Local inflammatory signs and 
venous stasis are frequent in advanced lesions. Alkaline phosphatase activity 
increases either moderately or evidently in serum, which is related to the osteoblastic 
activity of the basic tumour cell (Huvos, 1991; Schajowicz, 1994). Usually, an open 
biopsy is performed for histological diagnosis. 
The long bones of the extremities are the most common sites of osteosarcoma (Figure 
1.2.). The femur is involved in 44% ofall cases, the tibia in 17% and the humerus in 
15%. The femoral involvement occurs most frequently in the distal part of the bone, 
especially in the metaphysis or diaphysis (Cook, 1996). In fact, 51% of osteosarcoma 
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Figure 1.2. Skeletal distribution of osteosarcoma (Huvos, 1991). Most 
cases occured at the distal part of the femur. Half cases 
occurred around the knee region. 
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arises in the knee region. More than half of all osteosarcoma cases of the appendicular 
skeleton appear in patients who are under the age of 21. All other osseous or soft 
tissue sites are more common in skeletally mature older individuals. 
1.1.4. Treatment 
From experience, radiotherapy is not successfiil in either reliably controlling local 
recurrence or preventing the appearance of pulmonary metastases in osteosarcoma, 
even with doses that exceed normal tissue tolerance (de Moor, 1975). Complete 
surgical removal of the primary tumour, which can be an amputation or a limb 
salvage, is still the most reliable treatment of osteosarcoma. Although small 
pulmonary metastases may be successfully eliminated solely by aggressive 
chemotherapy, surgical removal of the primary tumour is still of critical importance 
(Douglass etal., 1975). 
Usually, surgical procedures are performed after pre-operative (neoadjuvant) 
chemotherapy. Previous reports have demonstrated that chemotherapy not only 
reduces the size of the primary tumour, but also entirely eradicates small tumours 
(Rosen et al., 1974; Rosen et aI., 1975). The potential advantages of neoadjuvant 
chemotherapy are to enhance operability by shrinking the tumour and delineating 
tumour margins, which in turn decreases the likelihood of local recurrence. 
Neoadjuvant chemotherapy also serves as an accurate in vivo sensitivity test in 
gauging the susceptibility of the patient's sarcoma to the chemotherapeutic agents 
employed. The information help us plan the adjuvant chemotherapy to be given after 
operation. 
At the Prince of Wales Hospital, the T-10 chemotherapy protocol is adopted for 
treating osteosarcoma patients ^ Figures 1.3. and 1.4.). This protocol was designed at 
the Memorial Sloan-Kettering Cancer Center in 1974 (Rosen & Nirenbe^, 1982; 
Rosen et a!., 1982). Previously, the 5-year survival of patients undergoing surgery 
alone seldom exceeds 20%. After the introduction of the T-10 protocol, the figure 
boosts to more than 80%. 
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Figure 1.4. Maintenance chemotherapy for osteosarcoma (Rosen et 
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is the main agent in combination chemotherapy. 
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1.2. Adriamycin 
Adriamycin (Doxorubicin) is an antitumour antibiotic first isolated in 1969 from 
Streptomyces peucetius (Arcamone et al, 1969). It is a natural product which belongs 
to a group of chemicals known as the anthracyclines. The drug consists of a 
naphthacenequinone nucleus linked via a glycosidic bond at position 7 to the amino 
sugar, daunosamine (Figure 1.5.). It has a molecular formula of C27H29NOn and a 
molecular weight of 543.54. At room temperature it is in the form of orange-red 
colored crystals and gives an orange-red aqueous solution at neutral pH. Clinically it 
is used to treat acute leukaemia, lymphoma and solid tumours including 
osteosarcoma, and is considered as the antineoplastic drug possessing the broadest 
spectrum of antitumour activity. 
1.2.1. Drug Action 
There are several proposed mechanisms for the action of adriamycin. However, the 
precise mechanisms of cytotoxicity remain a mystery. Mechanistic studies indicated 
that the anthracycline drugs can intercalate into DNA, form reactive metabolites 
which are bound to cellular macromolecules, induce lipid peroxidation, inactivate 
various enzymes, and induce topoisomerase II-dependent D N A strand breaks. Some 
investigators thought that adriamycin mediates its action by binding to D N A and 
intercalating adjacent base pairs, thus preventing nucleic acid synthesis (de Fraine et 
aL, 1990). In another study, antioxidant vitamins were reduced and plasma 
thiobarbituric acid reactants were significantly increased in cancer patients at the end 
of adriamycin chemotherapy (Faure et aL, 1996). These suggest that drug-induced 
hydrogen peroxide and hydroxyl radical formation may play a role in the 
antineoplastic action of adriamycin (Doroshow, 1986). Adriamycin induced 
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1.2.2. Pharmacology 
Adriamycin is administered intravenously over 3-5 minutes at a dosage of 60-75 
mg/m^ at 21-day intervals. The peak plasma drug concentration is 5 m M (Muller et al., 
1997). The drug is eliminated by metabolic conversion to a variety of less active or 
inactive metabolites by liver enzymes. A major pathway is the conversion to the 
alcohol doxorubicinol which also has cytotoxic activity like its parent (Figure 1.6.). 
This reduction is catalyzed by cytoplasmic NADPH-dependent reductases. However, 
the reduction of adriamycin by these enzymes is slow, compared to another 
antitumour anthracycline daunorubicin. Therefore a few hours after administration, 
the principal circulating form of adriamycin is still the parent drug. 
The major toxicity of adriamycin is in the heart. Since the anthracyclines are 
detoxified in the liver, patients with impaired hepatic function are at risk of severe 
toxicity and the dosage must be reduced as a result. At a total dose exceeding 
550mg/m^ the patient is susceptible to rapidly progressive syndrome of congestive 
heart failure and cardiomyopathy. Other common side effects of the drug include 
alopecia, bone marrow depression, nausea and vomiting. 
1.3. Multidrug Resistance 
Chemotherapy is a major part in any treatment protocol to deal with osteosarcoma. 
Despite the fact that it increases the 5-year survival rate significantly, the emergence 
of drug resistance often confers a big problem to clinical oncologists. In most cases, 
tumour cells develop resistance to several drugs belonging to a particular structural 
class. However, certain antibiotics and plant alkaloids with very different structures 
and biochemical mechanisms of action can select for cells that are cross-resistant 
between drug classes. As a result, the cells may be resistant to some drugs which they 
have never been exposed to before. This phenomenon is known as multidrug 
resistance (MDR) (Pratt etaL, 1994). 
M D R affects patients with a variety of hematological cancers and solid tumors 
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including those of the breast, ovarian, lung and lower gastrointestinal tract. Resistant 
cells generally show an unresponsiveness to chemotherapeutic agents. In the presence 
of cytotoxic drugs, sensitive cells are killed, leaving resistant cells which continue to 
grow. This explains why M D R is usually observed after a course of chemotherapy. 
There are several drug resistant mechanisms. The overexpression of membrane 
proteins, which control drug permeation, accelerates drug efflux, thus decreasing 
intracellular drug accumulation. For anthracycline antibiotics, free radicals are 
produced upon reduction. An enhanced antioxidative enzymes activities can scavenge 
excessive free radicals produced. A mutation in the topoisomerase II gene also 
prevents enzyme-dependent D N A strand breaks. 
1.4. P-glycoprotein 
In 1976, Juliano and Ling showed that a cell surface glycoprotein of 170kD was 
responsible for the drug resistance in Chinese hamster ovary cell mutants (Juliano & 
Ling, 1976). They designated it the P-glycoprotein (P-gp) (Figure 1.7.). 
1.4.1. Nature 
P-gp is a multidrug transporter which utilizes the energy of ATP to extrude a great 
variety of drugs from cells (Gottesman & Pastan, 1988). The protein is encoded by a 
small family of closely related genes, designated mdr, which includes two members in 
humans {MDRl, MDR2). The full length MDR\ c D N A encodes the whole P-gp 
molecule (Ueda et cd., 1986). P-gp is composed of 1280 amino acid residues, with a 
140kD protein core and 30kD N-linked carbohydrate. The molecule is highly 
symmetrical, with 12 predicted transmembrane domains (Chen et al., 1986; Richert et 
cd., 1988). Each half, known as a cassette, contains a very hydrophobic region and a 
hydrophilic region. It is thought that the two cassettes come together in the plasma 
membrane to form a channel for the energy-driven efflux of various drugs from the 
cell. 
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Gros and Chen found that the P-gp in tumour cells bears strong homology to a class of 
well-studied bacterial transporter proteins named permeases (Gros et al., 1986; Chen 
et al., 1986). The ATP-binding proteins of all of these permeases share extensive 
homology and are highly homologous to the hydrophilic portions of the M D R 
proteins. The homology includes, and extends far beyond, the ATP-binding site, 
indicating a strongly conserved functional similarity. 
1.4.2. Tissue Distribution 
P-gp is found in both normal and neoplastic tissues (van der Valk et al., 1990). It is 
localized to the luminal or apical surface of cells (Pratt et cd., 1994). Under normal 
conditions, it is distributed in the epithelium of various tracts and glands, for instance, 
the gastrointestinal tract and the salivary gland. It is also expressed in the endothelium 
of capillaries in various organs. Tumours arising from these normal tissues always 
have P-gp present. The presence ofP-gp on cells with secretory or excretory functions 
suggests its physiological role in the removal of potentially toxic substances from 
different organs, or its responsibility for the secretion of endogenous molecules. 
In the mineralizing region of human bones, P-gp is detected in growth plates 
(Mangham etaL, 1996). Immunohistochemical localization of P-gp to the perilacunar 
matrix in the hypertrophic zone of the growth plate, which gives the most intense 
staining, and to the osteoid matrix in the primary spongiosa, suggests the possibility 
of its association with matrix vesicles. Another point noteworthy is that P-gp contains 
two inwardly directed ATPase sites which may function as orthophosphate generators. 
It is believed that P-gp may play a role in chondrocyte hypertrophy. 
1.4.3. Relation with M D R 
P-gp mediated M D R is more commonly known as typical or classical M D R . P-gp 
contributes to drug resistance in about 50% of human cancers. In drug resistant 
bacteria or tumours cells, P-gp controls drug permeation by actively exporting 
intracellular drugs outside the cell. Overproduction of P-gp is thought to confer M D R 
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to tumour cells by decreasing the net intracellular accumulation of cytotoxic drugs. 
This overproduction has a genetic basis. It may be associated with gene amplification 
(de Bruijn et al., 1986) or with an increased rate of transcription of the MDR\ gene 
(van der Bliek et cd., 1988). Cytogenetic analysis of P-gp-mediated multidrug-
resistant sublines derived from human lung cancer cell line SW-1573 reveals 
translocations involving chromosome 7 at band q22. It is postulated that the 7q22 
translocation is casually linked to a high level of P-gp expression fN"ieuwint et cd., 
1992). 
1.5 Multidrug Resistance Protein 
Several tumour cell lines selected in vitro for resistance against natural product 
anticancer drugs do not show increased P-gp expression. Instead they have 
amplification and overexertion of the multidrug resistance protein (MRP) gene 
(Zaman et aL, 1993; Barrand et aI., 1994). 
The multidrug resistance protein (MRP) is first identified in 1990 (Marquardt et cd., 
1990). It is a 190 kD membrane glycoprotein comprised ofl531 amino acids (Cole & 
Deelay, 1993). The protein is a member of the superfamily of ATP binding transport 
proteins. The M R P gene is located on chromosome 16 and overexpression of it is the 
consequence of chromosomal amplification and fragmentation. However, there is a 
possibility that the M R P gene overexpressed in M D R cell lines is simply coamplified 
while the real gene responsible for M D R resides with the M R P gene on the same 
amplicon (Berrand et al, 1994). 
M R P has been detected in epithelia, muscle cells and macrophages (Flens et al., 
1996). Human lung tissues, both normal and neoplasmic, also show M R P expression 
(Giaccone et al., 1996). The actual subcellular location of the protein in multidrug 
resistant cells is not clearly elucidated. The protein is present primarily in the 
endoplastic reticulum but lower levels are also contained in the plasma membrane 
fraction (Berrand et al., 1994). In malignant tumours strong plasma membrane M R P 
staining was frequently observed, but in normal human tissues M R P staining was 
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predominantly cytoplasmatic (Flens et cd., 1996). 
The clinical importance of MRP is still undecided. Although it has a minor sequence 
homology with P-glycoprotein (McGrath et al., 1989), it is not clear whether the 
protein is involved directly in drug efflux. It is known that the level of expression of 
this protein in two series of non-small-cell lung tumour lines is closely associated 
with degree of resistance, with higher levels evident in the lines maintained at higher 
drug concentration (Barrand et al., 1994). The protein may have an excretory fiinction 
in protecting the organism against xenobiotics by exporting glutathione-conjugated 
endo- and xenobiotics (Muller et al., 1994). 
1.6. Reactive Oxygen Species 
Cells generate energy aerobically by reducing molecular oxygen to water. During 
electron transfer, partially reduced oxygen species are produced. In fact, 1-2% of total 
oxygen consumption may be converted to superoxide anion radical (.O2"), which is 
one of the reactive oxygen species (ROS). Other sources of R O S include radiation, 
toxic chemicals and drugs, e.g. adriamycin (Figure 1.8.). The superoxide anion radical 
may undergo spontaneous reduction to form hydrogen peroxide. This generated 
hydrogen peroxide is reduced in 3 ways: to be converted to less toxic substances by 
the cell, to be converted to hypochlorous acid by neutrophils and act as a bactericidal 
agent in phagocytic cells, or to be converted to the highly reactive hydroxyl radical 
spontaneously. The hydroxyl radical reacts instantaneously with any biological 
molecule, forming a more stable free radical (R&D, 1996). 
1.6.1. Problems Arising from R O S 
R O S are reactive species. They can react with all biological macromolecules. A 
radical can react with a macromolecule to generate a second radical, which in turn can 
react with a second macromolecule to continue the chain reaction (R&D, 1996). 
Among the more susceptible targets are the polyunsaturated fatty acids. The reaction 
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Figure 1.8. Generation of R O S (R&D, 1996). R O S can be 
generated by partial reduction of molecular oxygen 
or radiation, toxic chemicals and drugs, including 
adriamycin. 
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gives rise to many products, mostly alkanals and alkenals. R O S also modify the 
structure and function of proteins. They cause group additions, cross-links or 
fragmentation of proteins. Similarly, modification of nucleotide bases results in 
single-strand breaks and cross-links in D N A . 
1.6.2. Oxidative Stress and Diseases 
It is now believed that many diseases are associated with an abnormal metabolism of 
ROS. Atherosclerosis and ischaemia/reperfusion after myocardial infarction (Omar et 
al., 1991) are examples of oxidative-stress-associated cardiovascular problems. 
Neurological diseases, like, Alzheimer and Parkinson diseases, and musculoskeletal 
disorders, such as Duchenne muscular dystrophy (Hunter & Mohamed, 1986) and 
multiple sclerosis (Hunter etal., 1985) are also associated with ROS. 
Free radicals also initiate carcinogenesis by activating carcinogens (Gonzales et al., 
1984; Trush & Kensler, 1991). Most chemicals must first undergo metabolic 
activation to a biologically reactive intermediate to contribute to tumour promotion. 
This activation could be brought about by an oxidant generated by enzyme catalysis, 
or by the attack from oxidized biomolecules. 
1.6.3. Defense System 
R O S cause damage to cellular components. In order to minimize their damage, 
mammalian cells possess elaborate defense mechanisms to detoxify ROS. The key 
metabolic steps are the dismutation of superoxide to hydrogen peroxide and oxygen 
by superoxide dismutase, and the conversion of hydrogen peroxide to water by 
catalase and glutathione peroxidase (McCord & Fridovich，1969; Maddipati & 
Mamett, 1987) (Figure 1.9.). Other chemical antioxidants (e.g. vitamins C and E) 
terminate the chain reaction of radical damage by capturing the free radicals. 
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Figure 1.9. Adriamycin-induced oxyradicals formation and their 
removal by cellular antioxidative enzymes (Meijer et al., 
1990). The superoxide radical is converted into hydrogen 
peroxide by superoxide dismutase and then to water and 
oxygen by catalase or glutathione peroxidase. 
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1.6.4. Antioxidative Enzymes 
Superoxide dismutase (SOD) (EC 1.15.1.1) exists in two forms: Cu, Zn S O D which is 
found primarily in the cytoplasm, and the M n S O D which is found predominantly in 
mitochondria O?owers et al., 1978). The molecular weight of S O D is approximately 
31kD. Both isoforms catalyze the dismutation of superoxide ions into hydrogen 
peroxide and oxygen OFridovich, 1986). 
2 O2" + 2 H" • H2O2 + O2 
Catalase (EC 1.11.1.6) is a 240kD heme-containing tetrameric enzyme found mainly 
in peroxisomes and mitochondria (Aebi & Wyss, 1978; Chance et al., 1979). It 
catalyzes the conversion of hydrogen peroxide to oxygen and water: 
2 H2O2 • 2 H2O + O2 
Glutathione peroxidase (GPx) (EC 1.11.1.9) also exists in two forms: selenium 
dependent and selenium independent isoenzymes. The selenium-containing GPx is a 
tetrameric enzyme with molecular weight 84kD. It catalyzes the reduction of alkyl 
hydroperoxides to the corresponding alcohol by coupling to the glutathione redox 
cycle: 
R O O H + 2 G S H • R O H + GSSG + H2O 
The oxidized glutathione (GSSG) is reduced back to G S H by the dimeric flavoprotein 
glutathione reductase, at the expense ofNADPH: (Staal et al., 1969) 
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1.6.5. Relation with M D R 
Human cells are capable of activating adriamycin to its semiquinone status to generate 
secondary oxyradicals, except in adriamycin-resistant cells. Evidence shows that 
enzymes that detoxify superoxide and hydrogen peroxide significantly inhibit 
adriamycin-induced hydroxyl radical formation. This reduction in free radical 
formation in the nuclei and mitochondria of resistant cells may be significant in the 
protection of adriamycin-induced cell killing (Sinha et cd., 1987; Sinha et al., 1989). 
As a result, increased activities of antioxidative enzymes are thought to be one of the 
factors contributing to M D R for anthracycline drugs. 
1.7. Topoisomerase II 
During replication, helical D N A must first be unwound to relax the coil. The 
molecule's topology is controlled by two types of topoisomerases. Type I 
topoisomerase functions by creating transient single-strand breaks in D N A while type 
II topoisomerase modulates D N A topology by binding covalently with D N A and 
thereby generating a transient double-strand break in one double helix through which 
a second double helix is passed (Mirski & Cole, 1997). Topoisomerase II is a 
homodimer. Topo IIa has two 170kD subunits and topo Ep has two 180kD subunits. 
The two isoforms are encoded by distinct genes (Chung et a/.，1989). 
Ifthe topoisomerase II activity in a cell is reduced, fewer cleaved complexes can be 
formed and drug resistance may be the result (Figure 1.10.). The amount of 
topoisomerase II present in a cell may be regulated by protein turnover as well as by 
transcription, which is tightly controlled. Post-translational modification of the 
polypeptide or a mutation of the topoisomerase II gene may alter the enzyme's 
activity (Potmesil et al., 1987; de Isabella et al., 1991). However, the M D R associated 
with an altered topoisomerase H activity is a well-defined system of drug resistance 
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Figure 1.10. Catalytic cycle of topoisomerase II and generation of drug-
stabilized cleavable complexes (Mirski & Cole, 1997). The 
enzyme catalyses the unwinding of D N A by creating a transient 
double-strand break Some chemotherapeutic drugs appear to 
stabilize the transient DNA-topoisomerase II cleavable complexes 
by either increasing the forward rate of D N A cleavage or 
inhibiting D N A religation. 
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only in tissue culture models for which a clinical correlation has not been found yet 
due to limited clinical studies of the enzyme (Booser, 1997) 
1.8. Methods to Detect MDR 
Several methods have been developed to detect M D R on clinical specimens and 
cultured cells. The most widely adopted traditional method is the P-gp 
immunohistochemistry. The adriamycin binding assay is recently developed as an 
alternative. Both methods can be applied on clinical specimens as well as on cultured 
cells. 
1.8.1. P-glycoprotein Immunohistochemistry 
Immunohistochemistry is a special technique developed for the detection of cell 
surface and intracellular antigens in slices of fresh or fixed human (or animal) tissues 
by using antibodies. After incubation with a primary antibody reactive against a 
specific antigenic epitope, the tissues are treated with a second step antibody, raised in 
a different species, that binds the constant region of the primary antibody. This 
secondary antibody is conjugated to an enzymatic agent, such as biotin-avidin 
peroxidase complex, in several additional incubation steps. Finally, a chromogen (e.g. 
diaminobenzidine) is added, producing a reddish or brownish pigment. This color 
may be visualized on a glass slide using a light microscope, or be quantitated by 
optical density, using computer assisted image analyzer. Immunohistochemistry is the 
only method currently available for detecting protein expression in archival patient 
tissues stored in paraffin blocks. 
P-gp immunohistochemical studies on various cancers show that P-gp expression is 
associated with a poor prognosis in breast cancers (Schneider & Romero, 1995). 
Ovarian adenocarcinoma patients with P-gp-positive post-chemotherapy neoplasms 
are at three times greater risk of dying within 2 years than their counterparts with P-
gp-negative tumours (Khalifa et aI., 1997). P-gp positive patients are also at 
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significantly greater risk of disease recurrence (Gregorcyk et aI., 1996). In squamous 
cell carcinomas, only tumour cells at the invasion front express P-gp (Beer et al., 
1996). This makes some researchers believe that P-gp expression may enhance the 
invasive potential of tumour cells. Laboratory analysis confirms that the protein is 
found to be expressed more frequently in metastatic than in primary tumours. Its 
expression seems to be a marker of a more malignant phenotype (Linn et al., 1995). 
On the other hand, some claim that there is a strong reverse relation between P-gp 
expression and proliferative activity in endometrial adenocarcinomas (Kodama et al., 
1995). For instance, Nakagawa et al. showed that P-gp mediated multi-drug resistance 
might be induced after chemotherapy ofbladder tumors. However, the presence ofP-
gp before chemotherapy does not predict clinical outcome fNakagawa et al., 1997). 
1.8.2. Adriamycin Binding Assay 
Adriamycin is a natural fluorochrome. Intracellular adriamycin accumulation may be 
monitored by direct microscopic observation. Different patterns of fluorescence have 
been observed in living sensitive and resistant cells, and responsiveness to adriamycin 
has been associated with selective binding to the nucleus. The adriamycin binding 
assay (ABA) was developed in 1992 as a means to assess the chemosensitivity of 
clinical osteosarcoma specimens (Gebhardt et al., 1994). By observing the binding 
pattem of adriamycin in the tumour cells, the sensitivity of the tumour can be 
determined. It is shown that low levels of resistance in vitro, being not detectable by 
increased levels of expression of P-gp, can be revealed by the assay (Baldini et al., 
1992). However, its applicability on clinical specimens has not been demonstrated, 
nor has there been any report about the correlation between patients' A B A results and 
their clinical outcome. 
1.9. Aims of Study 
Early detection of multidrug resistance (MDR) in osteosarcoma patients may provide 
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clinicians with drug response and prognostic information. For drug resistant patients, 
suitable alternative treatment can be planned. Since classical M D R is mediated by P-
gp, an evaluation ofP-gp expression in biopsy samples may show intrinsic resistance. 
P-gp immunohistochemistry offers a way to measure the amount of P-gp expressed in 
a cell. However, the correlation of P-gp with clinical outcome remains controversial. 
Some authors reported that P-gp overexpression was associated with a poor prognosis, 
metastasis or even recurrence (Schneider & Romero, 1995; Linn et al., 1995; 
Gregorcyk et al., 1996). Others found no correlation between P-gp expression and 
patient outcome fNFakagawa et al., 1997; Nezasa et al,, 1997). On the other hand, the 
adriamycin binding assay has been proved to be a good method to determine in vitiv 
adriamycin resistance recently (Baldini et al., 1992), though its clinical application 
has not been established. In this study, we tested both methods on osteosarcoma 
samples to assess their correlation with tumour necrosis. 
Anticancer drugs have to gain access to tumour cells before they can exert their 
cytotoxic effects. An investigation on the effect of adriamycin on osteosarcoma cells 
help us to have a better understanding of the basis and the initial development of 
M D R . This may facilitate the development of new protocols to combat M D R . As 
mentioned above, anticancer quinones may kill tumour cells by multiple mechanisms 
and hydrogen-peroxide mediated events can predominate at lower drug concentrations 
(Doroshow, 1986). On the other hand, Lee and his co-workers reported that 
glutathione peroxidase activity was elevated during the initial development of 
adriamycin resistance (Lee et al., 1996b). Since both catalase and GPx catalyze the 
decomposition of hydrogen peroxide, therefore we treated osteosarcoma cells with a 
low dosage of adriamycin to evaluate their catalase and GPx activities. 
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2. MATEMALS AND METHODS 
2.1. Clinical Study 
Clinical osteosarcoma samples were subjected to the adriamycin binding assay and P-
gp immunohistochemistry. Post-chemotherapy osteosarcoma specimens removed by 
surgery were sent to a pathologist for tumour necrosis assessment. 
2.1.1. Patients Recruitment 
Osteosarcoma samples were obtained from patients admitted to the Department of 
Orthopaedics and Traumatology of the Prince of Wales Hospital. Patients were 
randomly chosen, regardless of their sex, age and the site involved. Their consensus 
was obtained before taking biopsy and surgical removal of the tumour. Biopsy 
samples were obtained before chemotherapy to confirm diagnosis. Surgical removal 
of tumour was performed after the patients had received one or more courses of 
chemotherapy. Both types of samples were subjected to the A B A and P-gp 
immunohistochemistry. Tumour necrosis was assessed by a pathologist only for 
samples taken after chemotherapy. 
2.1.2. Adriamycin Binding Assay 
Biopsy of osteosarcoma was taken from patients in the operating theatre. The sample 
was briefly washed with phosphate buffered saline (PBS) and sterilized after being 
immersed into 10% penicillin-streptomycin-neomycin (PSN) antibiotic mixture 
(15640-055, Gibco, Maryland) for 1-2 minutes. After a brief mechanical dissociation, 
the sample was treated with collagenase (C-6885, Sigma, St. Louis) at 37°C for at 
least 1 hour until adequate cell suspension was obtained. Tissue debris was removed 
by filtration through a lOOp.m membrane filter (Whatman, Massachusetts). After 
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adding more culture medium to dilute the collagenase, the cell suspension was 
centrifuged at l,500g for 5 minutes. The supernatant was aspired away and the cells 
were resuspended in fresh Iscove's Modified Dulbecco's Medium (EMDM) (I-7633, 
Sigma, St. Louis). The number of cells released was determined using a 
haemocytometer. Cell viability was determined using the trypan blue exclusion 
method. 
2 X 10^ cells were resuspended in 1ml E V O M . 5^ il adriamycin (Farmitalia Carlo Erba, 
Milan) solution was added. After incubating at 37°C for 30 minutes under continuous 
motion, 2ml fluorescein diacetate (F-7378, Sigma, St. Louis) solution was added and 
the cell suspension was further incubated for 10 minutes in the dark. 1ml PBS was 
then added to the suspension. After centrifugation at l,500g for 5 minutes, the cell 
pellet was resuspended in 50^ il medium and the cells were examined under a 
fluorescence microscope ( D M R photomicrography system, Leica, Wetzlar) with blue 
and green filters. 
Living cells were first identified using fluorescein diacetate fluorescence. Under blue 
excitation (blue filter), they showed green fluorescence, while dead cells did not 
(Figure 2.1.). Adriamycin sensitivity was then recorded under red excitation (green 
filter). Sensitive cells showed strong nuclear and weak cytoplasmic fluorescence. 
Resistant cells had weak diffuse cytoplasmic fluorescence without any distinctive 
intracellular binding OFigure 2.2.). The percentage of sensitive cells was calculated 
based on 300 living cells. According to Baldini, samples with 50% or more sensitive 
cells were regarded as sensitive whereas those with less than 50% sensitive cells were 
regarded as resistant. 
2.1.3. P-glycoprotein Immunohistochemistry 
P-gp immunohistochemistry was performed on osteosarcoma samples preserved in 
parafFin blocks. Both pre-chemotherapy and post-chemotherapy samples were used. 
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Figure 2.1. A fluorescence micrograph showing SaOS-2 cells stained 
with fluorescein diacetate (200x). Under blue excitation, 
living cells are stained green while dead cells are not. 
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Figure 2.2. A fluorescence micrograph showing adriamycin sensitive 
and resistant cells (200x). Under red excitation, sensitive 
cells show strong nuclear and weak cytoplasmic staining 
while resistant cells have weak staining without any 
distinctive intracellular binding. 
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2.1.3.1. Sample and Control Preparation 
Tumour samples from osteosarcoma patients were decalcified with 10% formic 
acid/formalin and fixed with 10% neutral buffered formalin for 2-3 days. They were 
dehydrated by upgraded alcohol series and embedded in paraffin. 5^m thick sections 
were cut using a microtome (Reichert-Jung 1130 Biocut, Leica, Nussloch). 
Human cervical carcinoma cell line KB-V1 served as the positive control for P-gp 
immunohistochemistry. The cell line is well-known for its high expression of P-gp on 
its surface (Cornwell et al., 1986). In order to mimic the tissue processing conditions 
that could influence immunoreactivity, a KB-V1 cell pellet was prepared. Preparation 
of cell culture cell blocks was described by Bratthauer (Bratthauer, 1994). Briefly, 
cells were cultured in a culture flask to confluence and then removed by the addition 
of Trypsin-EDTA (25200-056, Gibco, Maryland) solution. They were washed twice 
with PBS. To form a pellet, cells were centrifuged at l,500g for 10 minutes. Next, 
PBS was decanted and 10% neutral buffered formalin overlaid the pellet without 
causing disturbance. The pellet was fixed overnight at 4°C. Then the fixative was 
decanted and Milli-Q water overlaid the pellet. Carefully undermining the pellet with 
the needle of a syringe of Milli-Q water along the wall of the tube, the pellet was 
dislodged by rapidly expressing the syringe. To take out the pellet, it was swirled in 
Milli-Q water and quickly poured into a beaker. The Milli-Q water was removed and 
70% alcohol was added to cover the pellet. Then the pellet was processed as solid 
tissues in a processor (Reichert-Jung Histokinette 2000，Leica, Nussloch). It was 
dehydrated by up-graded alcohol and embedded into paraffin. Then 5p.m thick 
sections were cut using a microtome (Reichert-Jung 1130 Biocut, Leica, Nussloch). 
2.1.3.2, Immunohistochemical Procedures 
Osteosarcoma sections were deparafFinized in xylene and rehydrated in down-graded 
alcohol. After being rinsed in PBS, the tissue sections were briefly digested by trypsin 
(T-8253, Sigma, St. Louis). Endogenous peroxidase activity was quenched by 
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exposing tissue sections to 3 % H2O2 solution (18304, RDH, Seelze) for 10 minutes. 
Non-specific antibody binding was reduced by the addition of 1% bovine serum 
albumin (BSA) (A-9647, Sigma, St. Louis) to tissue sections for 20 minutes. The 
slides were incubated with primary antibody (SC-1517, Santa Cruz, California) at 
room temperature for 1 hour, and then secondary antibody (A-3540, Sigma, St. Louis) 
for 30 minutes. Colour was developed for 10 minutes in chromogen substrate 
solution. Haematoxylin was used as counterstain. All steps were repeated with the 
primary antibody substituted by the blocking solution on the negative control slide. 
Immunohistochemistry results were analyzed under a light microscope. P-gp positive 
cells were stained brown while negative cells did not (Figures 2.3. and 2.4.). 
2.1.4. Tumour Necrosis Assessment 
The effect of chemotherapy on primary sarcomas was assessed by a pathologist 
(Huvos, 1991). Osteosarcoma samples were cut into small blocks. The blocks were 
processed and embedded in paraffin for sectioning. Grades of response to pre-
operative chemotherapy were assigned following histological analysis of 
approximately 20-60 tissue sections (Table 2.1.). A grade I or II is considered no 
effect or a partial effect, which is regarded a "poor necrosis". A grade III or IV is 
considered a complete or near-complete effect, which is regarded a "good necrosis" 
(Figures 2.5. and 2.6.). 
2.2. Effect ofAdriamycin on Osteosarcoma Cells 
To study the effect of adriamycin on osteosarcoma cells, an in vitro model was 
established. 
2.2.1. Establishment of Adriamycin Adapted Osteosarcoma Cells 
Human SaOS-2 cell line CHTB-85) was purchased from the American Type Culture 
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Figure 2.3. A light micrograph showing positive P-glycoprotein 
immunostaining of paraffin embedded KB-V1 cells using 
diaminobezidine as substrate (200x). 
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Figure 2.4. A light micrograph showing negative P-gIycoprolein 
immunostaining of parafTin embedded KB-V1 cells using 
diaminobezidine as substrate (200x). 
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Grade Effects 
I Little or none. 
Areas of acellular tumour osteoid, necrotic, and/or fibrotic 
II material attributable to the effect of chemotherapy, with 
other areas of histologically viable tumour. 
Predominant areas of acellular tumour osteoid, necrotic, 
and/or fibrotic material attributable to the effect of 
III 
chemotherapy, with only scattered foci of histologically 
viable tumour cells. 
No histologic evidence of viable tumour within the 
IV . 
specimen. 
Table 2.1. Histologic grading of preoperative chemotherapy effects 
on primary osteosarcoma (Huvos, 1991). Grades I and II 
correspond to poor response. Grades III and IV 
correspond to good response. 
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Figure2.5. A light micrograph showing post-chemotherapy osteosarcoma 
taken from patient Y C Y stained with hematoxylin and eosin 
(200x). Good necrosis was observed as most tumour cells were 
killed by chemotherapeutic agents, leaving their nuclei behind. 
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Figure 2.6. A light micrograph showing post-chemotherapy osteosarcoma 
taken from patient SHL stained with hematoxylin and eosin 
(200x). Poor necrosis was observed as most tumour cells reamined 
viable. 
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Collection. It is a primary osteogenic sarcoma cell line derived from an 11 years old 
Caucasian female. The cells grow as a monolayer with an epithelial-like morphology 
(Figure 2.7.). 
2.2.1.1. Maintenance and Subculture of SaOS-2 Cell Line 
SaOS-2 cells were cultured in 150cm^ culture flasks (430824, Corning, 
Massachusetts). The cells were kept at 37。C, 5 % CO2 and 100% humidity. The 
culture medium was changed every 2-3 days. When confluence was reached, the 
medium in the culture flask was discarded and the cells were washed with PBS. 
Trypsin-EDTA solution (25200-056, Gibco，Maryland) was added to the monolayer 
and the culture flask was incubated at 37°C until the cells were well rounded and 
% 
began to detach. Cells were dislodged by sharply tapping the culture flask against the 
palm of hand. The action of trypsin was stopped by adding several milliliters of 
medium containing fetal bovine serum (FBS) to the cell suspension. The released 
cells were then transferred to a sterile centrifiige tube. The culture flask was rinsed 
with PBS and the solution pooled together. The cells were centrifuged at l,500g for 
10 minutes. After the supernatant was removed, the cell pellet was resuspended in 
fresh medium. Cell viability was determined under haemocytometer by the trypan 
blue exclusion method. lOjji cell suspension was mixed with lO^ il trypan blue 
solution and then placed in a haemocytometer. Under a light microscope, dead cells 
were stained blue while viable cells were not. The numbers of dead and viable cells 
were then counted respectively. Only the number of cells between 200 to 500 was 
accepted. SaOS-2 cell line was maintained by seeding 1 x 10^ cells to another 150cm^ 
culture flask containing the supplemented medium. 
2.2.1.2. Storage of Cell Line 
To store SaOS-2 culture, cells grown to confluence were trypsinized and centrifuged 
at l,500g for 10 minutes. The cell pellet was resuspended in supplemented medium at 
7 
a concentration of 1 x 10 cells/ml. 1ml cell suspension was dispensed aseptically into 
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Figure 2.7. A phase contrast inverted light micrograph showing SaOS-
2 cells in culture for 2 days (lOOx). The cells grow with an 
epithelial-like morphology. 
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a cryogenic vial and 50^1 dimethylsulphoxide (D-5879, Sigma, St. Louis) was added. 
The vial was frozen at -20。C overnight and then stored in liquid nitrogen. 
2.2.1.3. Adriamycin Treatment 
SaOS-2 cells were stepwisely exposed to 20ngAnl and 40ng/ml adriamycin 
(Farmitalia Carlo Erba, Milan) (Serra et al., 1993). 2 days after subculture, 
adriamycin was added to a final concentration of 20ng/ml. Cells were grown in this 
concentration of adriamycin for 2 weeks, and then stepped up to 40ngAnl. The cells 
were continuously cultured in the presence of adriamycin for at least 2 weeks before 
experiments. 
2.2.2. KB-V1 Cell Culture 
KB-V1 cell line is a gift from the City University of Hong Kong. The human 
epidermoid carcinoma cell line is a Hela variant. It is derived in vitro by a stepwise 
selection in the presence of vinblastine. 
Cell line maintenance and subculture procedures were the same as for SaOS-2 cell 
line. To maintain its expression of P-gp, vinblastine solution was added into the 
culture medium the following day after each subculture to a final concentration of 
lp.g/ml. 
2.2.3. Adriamycin Binding Asasy 
The assay procedures were the same as for clinical samples except that cell releasing 
steps were omitted. 
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2.2.4. P-glycoprotein Immunohistochemistry 
For immunostaining of cultured SaOS-2 cells, cytospin preparation ofKB-Vl served 
as the positive control. Both types of cells were harvested from cell culture as 
described. Cells were diluted to a concentration of 20,000 cells/ml. 1ml cell 
suspension was spun down on a glass slide (Cytospin, Shandon Lipshaw, 
Pennsylvania) at 1,000 rpm for 10 minutes. The slide was then fixed for 10 minutes in 
cold acetone as suggested by other investigators (Broxterman et al., 1989; Beck et cd., 
1996). Each cell patch contains 20,000 cells in 5 m m diameter. Immunohistochemical 
procedures were the same as for clinical samples. 
2.2.5. Thymidine Incorporation Assay 
D N A synthesis is an essential step in cell proliferation. Adenosine, thymidine, 
guanine and cytosine are the four bases composing a D N A molecule. Of these four 
bases, only thymidine is unique in a D N A . The thymidine incorporation assay makes 
use of this property to measure the rate of D N A synthesis (Stenberg, 1986). Tritiated 
thymidine is added into the culture medium for cells to take up. The radioactivity 
emitted from a cell's D N A is an index of its rate of D N A synthesis, which reflects its 
proliferation rate. 
2.2.5.1. Assay Procedures 
Osteosarcoma cells obtained from culture were diluted in supplemented medium. 2 x 
10^ cells were seeded into each well of a 24-well plate (430262, Corning, 
Massachusetts). The cells were incubated at 37°C, 5% CO2 and 100% humidity 
ovemight so that they can to adhere to the bottom of the plate. The next day，medium 
in each well was aspired. 300p,l (6^ j,Ci) freshly prepared labeled thymidine (TRK328, 
Amersham, Uppsala) solution was added. Then, the cells were incubated at 37°C, 5% 
CO2 for 4 hours. At the end of the incubation, the labeled thymidine solution was 
aspired and the wells were washed with 1ml PBS to remove any unincorporated 
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labeled thymidine. 
To lyse the cells, 250^1 0.25M N a O H was added into each well and after 15 minutes, 
the wells were rinsed with another 250jjl NaOH. The cell lysate was transferred into a 
centrifuge tube. 500^1 0.25M HC1 was added to neutralize the alkalinity. To 
precipitate D N A , 1ml 0.25mM Hepes with B S A solution was added into each tube, 
followed by 0.5ml 10M perchloric acid (524, Merck, Darmstadt). The solution was 
refrigerated at 4°C for another 30 minutes. 
After refrigeration, the tubes were centrifuged at 13,000 rpm at 4°C for 30 minute to 
pellet the B S A which carried the D N A . The supernatant was discarded and the pellet 
was resuspended in 0.5ml 0.25M NaOH. The solution was transferred to a counting 
vial and mixed with 4ml scintillation fluid. The number of counts per minute was 
recorded by a liquid scintillation counter (LS 3801, Beckman, California). 
Background radioactivity was measured in the same way by substituting the sample 
with0.5ml0.25MNaOH. 
2.2.6. Catalase Assay 
Catalase activity was measured by the method of Aebi (Aebi, 1984). The enzyme 
catalyzes the breakdown of hydrogen peroxide which has an absorption peak at 
240nm. By tracing the rate of hydrogen peroxide decomposition, the activity of 
catalase present in a sample could be calculated. 
2.2.6.1. Assay Procedures 
Cultured cells were trypsinized and washed twice with PBS. 2 x 10^ cells were 
resuspended in 200|il potassium phosphate buffer. The cells were lysed by sonication 
(Soniprep, MSE, Montana) at 14 microns wavelength for 3 x 20 seconds. The lysate 
were centrifuged at 12,000g at 4°C for 45 minutes to spin down cell debris. The 
supernatant was collected and catalase assay was carried out immediately. 
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lOOjjJ[ sample solution and 2.9ml substrate solution were mixed in a 3ml quartz 
cuvette. The absorbance at 240nm was monitored by a spectrophotometer (DU 650, 
Beckman, California) for 1 minute. Potassium phosphate buffer served as the blank. 
2.2.6.2. Unit Calculation 
One unit of catalase activity is defined as the amount that decomposes l^mol 
hydrogen peroxide/min/mg protein at pH 7, 25°C. The molar absorptivity of hydrogen 
peroxide at 240nm is taken as 39.4 M"^ cm"^ CNelson 8c Kiesow, 1972). 
2.2.7. Glutathione Peroxidase Assay 
The GPx activities in parental and resistant cells were measured using the method 
proposed by Paglia and Valentine (Paglia & Valentine’ 1967). The glutathione redox 
system is coupled to the consumption of H2O2 and NADPH. GPx catalyzes the 
conversion of reduced glutathione (GSH) to the oxidized form (GSSG) and vice 
versa. The rate of GSSG formation is an index of GPx activity, which is measured by 
following the decrease in absorbance of the reaction mixture at 340nm as N A D P H is 
converted to NADP+. 
2.2.7.1. Assay Procedures 
Cultured cells were trypsinized and washed twice with PBS. 2 x 10^ cells were 
resuspended in 200^ il potassium phosphate buffer with l m M EDTA. The cells were 
lysed by sonication (Soniprep, MSE, Montana) at 14 microns wavelength for 3 x 20 
seconds. The lysate were centrifuged at 12,000g at 4。C for 45 minutes to spin down 
cell debris. The supernatant was collected and GPx assay carried was out 
immediately. 
To a 1ml quartz cuvette 400p,l potassium phosphate buffer with l m M EDTA, lOO^ il 
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glutathione reductase solution, lOO^ il reduced glutathione solution, lOOpil N A D P H , 
lOOp.1 sodium azide solution and \00[i\ sample were added. 100pJ substrate solution 
was added and the absorbance at 340nm was recorded for 2 minutes. Potassium 
phosphate buffer with l m M E D T A served as blank. Background oxidation was 
determined by substituting the sample with equal volume of potassium phosphate 
buffer with l m M EDTA. 
2.2.7.2. Unit Calculation 
One unit of GPx activity is defined as the amount that oxidizes lnmol 
NADPH/min/mg protein at pH 7, 25。C. The molar absorptivity o f N A D P H at 340nm 
is taken as 6.3 x 10^  M ] cm'^ (Bergmeyer, 1975). 
2.2.8. Protein Determination 
Protein assays using Bio-Rad Protein Assay Dye Reagent Concentrate (500-0006, 
Bio-Rad) were based on the method of Bradford (Bradford, 1976). It is a dye-binding 
assay in which a differential color change of a dye occurs in response to different 
concentrations of protein. 
The microassay procedures for microtiter plates (430247, Coming, Massachusetts) 
were employed. The linear range of the assay is from 8^ig/ml to approximately 
80^ ig/ml. B S A standard solutions were prepared at 0, 10, 20, 40, 80 p<gAnl. 
160pi of each standard or sample solution was mixed thoroughly with 40pJ dye 
reagent concentrate in separate microtiter plate wells. The mixture was allowed to 
incubate at room temperature for 15 minutes. Absorbance at 595nm was recorded 
using a microplate reader (MR 600, Dynatech, Sussex). Protein content in the sample 
can be determined from the standard curve. 
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2.3. Statistical Analysis 
Due to the small sample size in some groups, Fisher's exact test was used to evaluate 
the association between two dichotomous variables in the clinical study. To compare 
the proliferation rate and enzyme activities of cells maintained at different adriamycin 
concentrations, one-way A N O V A was used to calculate the significance. Normally, 
p<0.05 is regarded as significantly different. 
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3. RESULTS 
3.1. Clinical Study 
Biopsy samples were obtained before chemotherapy to confirm diagnosis. Surgical 
removal of tumour was performed after the patients had received one or more courses 
of chemotherapy. Both types of samples were subjected to the A B A and P-gp 
immunohistochemistry. Tumour necrosis was assessed by a pathologist only for 
samples taken after chemotherapy. All the results are described as followed. 
3.1.1. Patients Recruitment 
A total of 26 osteosarcoma patients were recruited into our clinical study during the 
period 7/1996 to 6/1998. Their age ranges from 7 to 67 years old. 12 (46.15%) of 
them were between 10-19 years old. There were 13 male and 15 female patients. The 
male to female ratio was 0.87:1. The site involved in most patients (60.71%) was the 
distal femur. 
The results are summed up in Table 3.1. and the they will be further analyzed in detail 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.1.2. Correlation ofAdriamycin Sensitivity to Tumour Necrosis 
Pre-chemotherapy A B A was carried out in 26 patients. 14 (53.85%) of them were 
adriamycin sensitive (Table 3.2.). Among them, 8 (57.14%) had good necrosis and 6 
(42.86%) had poor necrosis. 12 (46.15%) patients were adriamycin resistant (Table 
3.3.). 2 (16.67%) of them had good necrosis and the other 10 (83.33%) had poor 
necrosis. Statistical analysis using the Fisher's exact test gave a p value of 0.042. It 
indicated a statistically significant correlation between pre-chemotherapy adriamycin 
sensitivity and good necrosis. 
Post-chemotherapy A B A was carried out in 7 patients. 3 (42.86%) of them were 
adriamycin sensitive (Table 3.4.). Among them, 2 (66.67%) had good necrosis and 1 
(33.33%) had poor necrosis. 4 (57.14%) patients were adriamycin resistant (Table 
3.5.). All (100%) of them had poor necrosis. Statistical analysis using the Fisher's 
exact test gave a p value of 0.143. There is no statistically significant correlation 
between post-chemotherapy adriamycin sensitivity and good necrosis. 
After chemotherapy, 3 patients had their adriamycin sensitivity increased and 3 
decreased. The sensitivity of one patient did not change. He remained adriamycin 
resistant. 
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Code A B A Results Necrosis 
Y C E Sensitive Good “ 
L Y M Sensitive Good 
Y C Y Sensitive Good “ 
B W Y Sensitive Good _ 
L C K Sensitive Good 
LSF Sensitive Good 
N K Y Sensitive Good 
C C H Sensitive Good 
W T F Sensitive Poor 
KP Sensitive Poor 
M C W Sensitive Poor 一 
LCS Sensitive Poor 
SHL Sensitive Poor 
HS Sensitive Poor 
Table 3.2. Pre-chemotherapy adriamycin binding assay 
showed that 14 patients were adriamycin 
sensitive. 8 (57.14%) of them had good necrosis 
and 6 (42.86%) of them had poor necrosis. 
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Code A B A Results Necrosis 
L W Resistant Good 
M L K Resistant Good 
K S W Resistant 一 Poor “ 
H B Resistant Poor 
TI Resistant Poor 
W C W Resistant — Poor ~ " 
C K L — Resistant Poor 
C M S Resistant Poor 
L W F Resistant Poor 
C A K Resistant Poor 
C S Y Resistant Poor 
CL Resistant Poor 
Table 3.3. Pre-chemotherapy adriamycin binding assay 
showed that 12 patients were adriamycin 
resistant. 2 (16.67%) of them had good necrosis 
and 10 (83.33%) of them had poor necrosis. 
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Code A B A Results Necrosis 
L W Sensitive Good 
M L K Sensitive Good 
H B Sensitive Poor 
Table 3.4. Post-chemotherapy adriamycin binding assay 
showed that 3 patients were adriamycin sensitive. 
2 (66.67%) of them had good necrosis and 1 
(33.33%) of them had poor necrosis. 
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Code A B A Results Necrosis 
LCS 一 Resistant Poor 
SHL Resistant Poor 
C K L Resistant Poor 
HS Resistant Poor 
Table 3.5. Post-chemotherapy adriamycin binding assay 
showed that 4 patients were adriamycin resistant. 
All (100%) of them had poor necrosis. 
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3.1.3. Correlation of P-glycoprotein Expression to Tumour Necrosis 
Pre-chemotherapy P-gp expression was assessed in 18 patients. Low P-gp expression 
was found in 16 (88.89%) patients (Table 3.6.). Among them, 5 (31.25%) had good 
necrosis and 11 (68.75%) had poor necrosis. 2 (11.11%) patients had high P-gp 
expression (Table 3.7.) and both of them had good necrosis. Statistical analysis using 
the Fisher's exact test gave a p value of 0.137. There was no statistically significant 
correlation between pre-chemotherapy low P-gp expression and good necrosis. 
Post-chemotherapy P-gp expression was assessed in 14 patients. Low P-gp expression 
was found in 3 (21.43%) patients (Table 3.8.). Among them, 1 (33.33%) had good 
necrosis and 2 (66.67%) had poor necrosis. 11 (78.57%) patients had high P-gp 
expression (Table 3.9.). 2 (18.18%) of them had good necrosis and 9 (81.82%) had 
poor necrosis. Statistical analysis using the Fisher's exact test gave a p value of 0.547. 
There was no statistically significant correlation between post-chemotherapy low P-
gp expression and good necrosis. 
13 patients had the pre-chemotherapy and post-chemotherapy P-gp expression 
evaluated. P-gp expression was found to have increased in 8 (61.54%) patients after 
chemotherapy. 5 (38.46%) patients had no change and no patients showed a reduction 
in P-gp expression. Figures 3.1. and 3.2. show the change in P-gp expression in 
patient TI after chemotherapy. 
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Code P-gp Expression Necrosis 
Y C E — ^ Good — 
L Y M Low Good 
Y C Y Low “ Good “ 
M L K Low — Good 
LSF Low Good — 
W T F Low — Poor — 
KP Low Poor 
M C W Low 一 Poor — 
K S W 一 Low 一 Poor 
H B Low Poor 
TI Low Poor 
LCS Low Poor 
SHL Low Poor 
C K L Low ~ Poor — 
HS Low ~ Poor — 
C M S Low Poor 
Table 3.6. Pre-chemotherapy P-glycoprotein immunohistochemistry 
showed that 16 patients had low P-glycoprotein 
expression. 5 (31.25%) of them had good necrosis and 11 
(68.75%) ofthem had poor necrosis. 
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Code P-gp Expression Necrosis 
B W Y — U ^ Good — 
L W H i i Good 
Table 3.7. Pre-chemotherapy P-glycoprotein immunohistochemistry 
showed that 2 patients had high P-glycoprotein 
expression. All (100%) of them had good necrosis. 
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Code P-gp Expression Necrosis 
Y C Y “ ^ Good -
LCS — 1 ^ Poor 
C K L Low Poor 
Table 3.8. Post-chemotherapy P-glycoprotein immunohistochemistry 
showed that 3 patients had low P-glycoprotein expression. 
1(33.33%) of them had good necrosis and 2 (66.67%) of them 
had poor necrosis. 
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Code P-gp Expression Necrosis 
B W Y 一 High Good 
L W “ 1 ^ Good — 
W T F 一 High _ Poor 
KP High — Poor 
M C W 一 B ^ Poor “ 
H B — High Poor — 
- TI High Poor 
W C W 一 ffigh Poor — 
SHL 一 B ^ Poor — 
HS — High Poor 
C M S Hi;h Poor 
Table 3.9. Post-chemotherapy P-glycoprotein immunohistochemistry 
showed that 11 patients had high P-glycoprotein expression. 
2(18.18%) of them had good necrosis and 9 (81.82%) of them 
had poor necrosis. 
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Figure 3.1. A light micrograph showing low P-glycoprotein 
immunostaining in pre-chemotherapy osteosarcoma from 
patient TI using diaminobezidine as substrate (200x). 
58-
•厂二％ ) ,々】 / ?— ^ 1二 &么虛倉 | 7 氣 4 广 嫩 1 / - > ^ , -
!•，^' I . # V、在 4 二 鲁：如攀-‘必 M ；— » 广 _ 辜，，‘ 
% % n S ' - ^ , ^ - ： > / | ； - ^ ： - ^ ： ； ^ . 
# ^i /, f _ 響- .» 1^ -- #^ W. t 糖- »承 ^ . * ^  “ ? 
- - ^ i 7 4 | 感 參 : ’ ， i ) • ' , d “ , ‘ 
‘ % ^ - , ^ # ^ ^ r ^ | ^ ^ ^ ^ - -
f r v ^ " f ^ | ^ - . < . ' k ; — / M ^ - ^ 
-J i# M * 、參 _*ltlmr^4 —- J ^ ‘ 1 
. • ^ n f . - - 3 f e . - — ’ i > � : : 5 r L � ‘ - f vi.-fc：, 
勢 ） / ‘ / ¾ ¾ & ¾ . m 么 ^ * ? , ， 
i p . 4 ' 之 种 , ; : - ： 也 ： : 气 % M X ' j ' ^-‘ 
^ j - ^ m r . ^ ^ - > ^ ^ ¾ ' ¾ 
' ^ ^ p w < f g % # - f ^ ' , f t ‘ ^ • § , % . 
# - # ^ 4 f ^ r ^ _ 
% ^ • - 』 鮮 办 t % 4 l 
m^mm^^ 
Figure 3.2. A light micrograph showing high P-gp immunostaining in 
post-chemotherapy osteosarcoma from patient TI using 
diaminobezidine as substrate (200x). 
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3.1.4. Correlation of P-glycoprotein Expression to Adriamycin Sensitivity 
A total of 23 samples, either pre-chemotherapy or post-chemotherapy, had their 
adriamycin sensitivity and P-gp expression assessed. 12 samples (52.17%) were 
adriamycin sensitive (Table 3.10.). Among them, 9 (75%) had low P-gp expression 
and 3 (25%) had high P-gp expression. 11 (47.83%) samples were adriamycin 
resistant (Table 3.11.). 8 (72.73%) ofthem had low P-gp expression and 3 (27.27%) 
of them had high P-gp expression. Statistical analysis using the Fisher's exact test 
gave a p value of 0.590. There was no statistically significant correlation between 
adriamycin sensitivity and low P-gp expression. 
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Code A B A Results P-gp Expression 
Y C E Sensitive Low  
L Y M Sensitive Low  
Y C Y Sensitive Low  
W T F — Sensitive Low  
KP Sensitive Low  
M C W Sensitive Low  
LCS Sensitive Low  
SHL Sensitive Low  
H S Sensitive Low  
— B W Y Sensitive High 一 
L W Sensitive High  
H B Sensitive High 
Table 3.10. P-glycoprotein immunohistochemistry was performed on 
12 adriamycin sensitive samples. 9 (75%) had low P-
glycoprotein expression and 3 (25%) had high P-
glycoprotein expression. 
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Code A B A Results P-gp Expression 
M L K Resistant Low  
K S W Resistant ] ^  
H B Resistant Low  
TI Resistant Low  
LCS Resistant Low  
C K L Resistant Low  
C K L Resistant Low  
C M S Resistant Low  
L W — Resistant High  
SHL Resistant High  
H S Resistant HighT" 
Table 3.11. P-glycoprotein immunohistochemistry was performed on 
11 adriamycin resistant samples. 8 (72.73%) had low P-
glycoprotein expression and 3 (27.27%) had high P-
glycoprotein expression. 
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3.2. Effect of Adriamycin on Osteosarcoma Cells 
A B A and P-gp immunohistochemistry were performed on SaOS-2 cells harvested 
from the culture to determine the drug sensitivity of SaOS-2 cells as adriamycin 
concentration in the culture medium was increased. The proliferation rate of the cells 
was determined by the thymidine incorporation assay. Catalase and GPx activities of 
cells were measured by the corresponding enzyme assay. 
3.2.1. Adriamycin Sensitivity and P-glycoprotein Expression 
All SaOS-2 cells cultured, either in the presence of in the absence of adriamycin, were 
not stained by P-gp immunohistochemistry. However, A B A revealed that the 
sensitivity of the cells decreased when the drug concentration was stepped up (Table 
3.12.). 
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Adriamycin Concentration in Medium Ong/ml 20ng/ml 40ngAnl 
Adriamycin Sensitivity (%) 18 6 0 
P-gp Expression --- … _— 
Table 3.12. Adriamycin sensitivity and P-gp expression were 
determined in SaOS-2 cells treated with different 
concentrations of adriamycin. Sensitivity was 
decreased as adriamycin concentration was 
increased, although P-gp expression remained 
undetectable. 
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3.2.2. Thymidine Incorporation Rate 
The change in the amount of thymidine incorporated by SaOS-2 cells after the 
adriamycin treatment was shown in Figure 3.3. A decrease in the amount of 
thymidine incorporated was observed when SaOS-2 cells were cultured in the 
presence of adriamycin. When 20ng/ml adriamycin was added into the culture 
medium, the amount ofthymidine incorporated by the cells dropped to 49.02% ofthe 
original. When the drug concentration was stepped up to 40ng/ml, the figure 
decreased to 20.52% of the original. 
Statistical analysis using the 1-way A N O V A gave a p value of less than 0.001. There 
was statistically significant correlation between the proliferation rate of SaOS-2 cells 
and adriamycin concentration. 
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Thymidine Incorporation Rate of SaOS-2 Cell Line 
Cultured at Various Concentrations of Adriamycin 
1.6 n ： 
14 ^ ^ — 
0 ^ 1-2 ——•• 
^ ^ H 
1 s 1.0 m ^ m  
mBm 
^ 1 0 . 8 ——m - n r ~  
I I。.6 • _ 
^ - 0.4 w M m^M  
- - • • • 
0.0 ^ ^ i ^ 1 ^  
0 20 40 
Adriamycin concentration (ng/ml) 
Figure 3.3. A graph showing the amount of thymidine incorporated by 
SaOS-2 cells cultured at different adriamycin concentrations 
(n=4). The amount of thymidine incorporated decreased as 
adriamycin concentration was increased. 
66-
3.2.3. Intracellular Concentration of Catalase 
The change in catalase activity of SaOS-2 cells after the adriamycin treatment was 
shown in Figure 3.4. A decrease in the catalase activity was observed when SaOS-2 
cells were cultured in the presence of adriamycin. When 20ngy^ml adriamycin was 
added into the culture medium, the catalase activity of the cells dropped to 41.70% of 
the original. When the drug concentration was stepped up to 40ngAnl, the figure 
decreased to 22.95% of the original. 
Statistical analysis using the 1-way A N O V A gave a p value of 0.127. There was no 
statistically significant correlation between catalase activity and adriamycin 
concentration. 
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Intracellular Catalase Activity of SaOS-2 Cell Line 
Cultured at Various Concentrations ofAdriamycin 
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Figure 3.4. A graph showing the catalase activity of SaOS-2 cells cultured at 
different adriamycin concentrations (n=5). Catalase activity 
decreased as adriamycin concentrations was increased. 
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3.2.4. Intracellular Concentration of Glutathione Peroxidase 
The change in GPx activity in SaOS-2 cells after the adriamycin treatment was shown 
in Figure 3.5. A decrease in the GPx activity was observed when SaOS-2 cells were 
cultured in the presence of adriamycin. When 20ng/ml adriamycin was added into the 
culture medium, the GPx activity of the cells dropped to 60.46% of the original. 
When the drug concentration was stepped up to 40ng/ml, the figure decreased to 
44.08% ofthe original. 
Statistical analysis using the 1-way A N O V A gave a p value of 0.057. There was no 
statistically significant correlation between GPx activity and adriamycin 
concentration. 
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Intracellular Glutathione Peroxidase Activity of SaOS-2 Cell Line 
Cultured at Various Concentrations of Adriamycin 
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Figure 3.5. A graph showing the glutathione peroxidase activity of SaOS-2 
cells cultured at different adriamycin concentrations (n=4). 
Glutathione peroxidase activity decreased as adriamycin 
concentration was increased. 
70-
4. DISCUSSIONS 
4.1. Clinical Study 
In order to compare the applicability of the adriamycin binding assay and P-gp 
immunohistochemistry to predict tumour necrosis in osteosarcoma patients, we have 
to compare the correlation of A B A results and that of P-gp immunohistochemistry 
data with tumour necrosis. 
4.1.1. Patients Recruitment 
Osteosarcoma is the most common primary bone cancer in Hong Kong. In our 
hospital, 7-10 patients are newly diagnosed and admitted each year. During pre-
operative chemotherapy, about 15-20% patients will drop out or succumb. Some 
patients do not accept surgical treatment and seek alternatives. This makes it difficult 
to collect post-chemotherapy samples. 
Data from the Memorial Sloan-Kettering Cancer Center in the N e w York City show 
that the proportion of male to female patients is 1.3:1 (Huvos, 1991). Among our 
patients, the number of female patients is more than that of male. This may be due to 
our small sample size. The age distribution and the site involved in most cases 
matches with what is reported previously by the Memorial Sloan-Kettering Cancer 
Center. 
4.1.2. Correlation between Adriamycin Sensitivity and Tumour Necrosis 
The adriamycin binding assay (ABA) is a quick method to determine tumour response 
towards adriamycin. It is sensitive and easy to perform. The shortcomings are that the 
specimens must be alive and adequate number of cells must be released from a 
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tumour in order to verify the accuracy of the assay. Problems may arise when dealing 
with post-chemotherapy samples as most cancer cells may have already been killed by 
cytotoxic agents. In this study, the A B A was performed on tumour cells released from 
fresh osteosarcoma samples. This ruled out the possibility that in vitro culture might 
alter the physiological behaviour of the cells. Besides, quite often, cells may show 
binding pattern in between the sensitive and the resistant binding patterns. This makes 
it difficult to classify cells into the sensitive or the resistant phenotype. In such cases, 
an experienced worker is required to categorize the cells. 
Pre-chemotherapy adriamycin sensitivity was found to has statistically significant 
correlation with tumour necrosis. This means that osteosarcoma patients who are 
adriamycin sensitive at the clinical onset should have a good tumour necrosis, and 
vice versa. Although A B A is a convenient method to detect clinical drug resistance, 
very few reports on using it to predict either tumour necrosis or patients survival can 
be found. Perhaps it is because the use of it on clinical samples has not been studied. 
It is suggested that pre-chemotherapy A B A should be used as an index to predict the 
clinical outcome. 
Drug resistance may occur either at the onset, as an intrinsic feature of the tumour, or 
later on, after several courses of chemotherapy. Detection of P-gp activity in pre-
chemotherapy tumour samples may not be able to show resistance. Besides, low level 
of resistance cannot be detected by P-gp immunohistochemistry. Therefore the use of 
A B A together with an estimation of P-gp expression is recommended to serve as an 
accurate means of predicting the sensitivity of osteosarcoma to adriamycin (Baldini et 
al., 1992). This combination also helps to confirm whether the resistance is due to an 
overexpression ofP-gp or not. 
The correlation between post-chemotherapy A B A results and tumour necrosis was 
found to be insignificant. Due to the small sample size, this p value my not be 
reliable. 3 patients had their adriamycin sensitivity decreased after chemotherapy. W e 
believe that it is because in these patients, drug resistance is induced during 
chemotherapy, as a result of the cytotoxic pressure exerted by the chemotherapeutic 
agents. On the other hand, 3 patients had their adriamycin sensitivity increased after 
chemotherapy. This may be due to the tissue sampling error induced during surgical 
‘ 72 
operations. 
4.1.3. Correlation between P-glycoprotein Expression and Tumour Necrosis in 
Osteosarcoma 
Based on this study, it was found that P-gp in osteosarcoma was induced during 
chemotherapy, but it cannot be used as a prognostic factor to predict tumour necrosis 
clinically. 
4.1.3.1. P-glycoprotein Is Induced During Chemotherapy 
It has been reported that P-glycoprotein (P-gp) overexpression may be an inherent 
feature ofosteosarcoma, soft tissue sarcoma or breast cancer (Serra et cd., 1995; Serra 
et al., 1996; Gregorcyk et al., 1996). Among our patients, P-gp expression was 
observed before any treatment was given. P-gp was expressed intrinsically in our 
patients. 
Our data showed that before chemotherapy, only 2 out of the 18 (11.11%) samples 
had high P-gp expression. After chemotherapy, 11 out of 14 (78.57%) samples had 
high P-gp expression. Among the individual patients, the P-gp expression of 8 
patients had increased and that of 5 patients had no change after chemotherapy. No 
patient had a decrease in P-gp expression. All these data showed that P-gp was 
induced during chemotherapy. 
The induction of P-gp was reported in bladder cancer. Nezasa and his co-workers 
CNezasa et al., 1997) reported that in a group of 14 patients who had bladder cancer, 
clinical specimens were obtained before and after neoadjuvant intra-arterial 
chemotherapy. The expression levels ofMDRl m R N A were significantly higher in 
the post-treatment specimens than in the pre-treatment specimens. Nakagawa and his 
co-workers also showed that P-gp mediated multi-drug resistance might be induced 
after chemotherapy fNfakagawa et al., 1997). 
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It is thought that in the initial stage of adriamycin exposure, P-gp expression in 
tumour cells is generally low and overexpression of the protein is not the main factor 
that confers drug resistance to the tumour (Lee et al., 1996a). As incubation time 
increased, the tumour cells have to pump out the drug diffused into them in order to 
survive. P-gp expression is induced and classical M D R results. Increased protein 
expression can be due to an increased rate of gene transcription or m R N A translation. 
It is reported that for P-gp, the expression of the protein does not reliably correlate 
with the level of the MDR\ expression (Kandel et al., 1995). Furthermore, in most 
cases ofosteosarcomas, MDR\ expression is not induced following chemotherapeutic 
treatment (Lee et al., 1996a). Therefore it is believed that the increased P-gp 
expression after chemotherapy is due to an enhanced rate of MDR\ m R N A 
translation. 
4.1.3.2. P-glycoprotein Cannot Serve As a Prognostic Factor 
In human sarcoma M D R may be the result of an overexpression of P-gp and this 
overexpression may be an inherent feature (Gerlach et al., 1987; Serra et al., 1996). In 
most cases, MDR\ expression is not induced following chemotherapeutic treatment 
(Lee et al., 1996a). Analysis of P-gp expression reveals that P-gp is undetectable in 
the two low-grade lesions, grades III and IV. Besides, the percentage of metastatic 
osteosarcoma showing an increased level of P-gp expression is significantly higher 
compared to primary lesions (Serra et al., 1995). Detectable P-gp appears to be an 
important adverse prognostic factor and consistent absence of the protein is associated 
with a more favourable prognosis (Chan et aL, 1990). 
In osteosarcoma, Serra and his co-workers reported that P-gp overexpression is 
associated with a poor clinical outcome, and an evaluation of P-gp expression in 
clinical samples at the clinical onset might be useful to identify those patients who 
would have a poor response to chemotherapy (Serra et al., 1995) 
It is found that in patients with high-grade osteosarcoma treated with surgery and 
chemotherapy, overexpression of P-gp after chemotherapy in tumour cells is 
associated with a significantly increased risk of adverse events and is independent of 
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the extent of necrosis after preoperative chemotherapy (Baldini et cd., 1995). P-
glycoprotein status and the extent of tumour necrosis after preoperative chemotherapy 
are independent predictors of clinical outcome. 
In our study, we found that the correlation between either pre-chemotherapy or post-
chemotherapy P-gp expression with tumour necrosis was not statistically significant, 
although the protein was induced after chemotherapy. It is believed that P-gp cannot 
serve as an index of clinical outcome. Although adriamycin can act as a potent acute 
inducer of functional P-gp (Fardel et al., 1997), in the early phases of resistance 
development and in inherent resistance present at clinical onset, detection of P-gp 
may not be able to show resistance (Baldini et al., 1992). This tells the reason why 
pre-chemotherapy A B A can serve as an index of clinical outcome instead of pre-
chemotherapy P-gp expression. 
Within our group, 11 patients (78.57%) have high P-gp expression after 
chemotherapy. It is reported that in ovarian adenocarcinoma, P-gp positivity in post-
chemotherapy tumours is a better predictor of patients' survival than the occurrence of 
persistence or recurrence (Khalifa et al., 1997). In this study, we used tumour necrosis 
as an index of chemotherapeutic response. Since the follow up period of most patients 
is within one year, the correlation between P-gp expression and patients' survival was 
not calculated. 
4.1.4. Correlation Between Adriamycin Sensitivity and P-glycoprotein 
Expression 
W e found that the correlation between adriamycin sensitivity and P-gp expression in 
our osteosarcoma samples was not statistically significant. W e cannot determine the 
P-gp expression of a given osteosarcoma sample by measuring its adriamycin 
sensitivity. The adriamycin sensitivity of our samples was not mainly due to P-gp 
overexpression. The change in sensitivity may be caused by other mechanisms such 
as elevated antioxidative enzymes activities or a mutation in the topoisomerase II 
gene. 
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4.2. Effect ofAdriamycin on Osteosarcoma Cells 
To further investigate whether clinical adriamycin resistance is due to an enhanced 
antioxidative enzymes activities, we studied the effect of adriamycin on the catalase 
and GPx activities ofosteosarcoma cells treated with a low concentration (20ng/ml & 
40ng/ml) of adriamycin. 
4.2.1. Adriamycin Sensitivity and P-glycoprotein Expression 
The adriamycin treated osteosarcoma cells are not resistant variants of the parental 
cell line. Although A B A revealed that their sensitivity decreased, no P-gp expression 
was observed. In another study, Lee and his co-workers treated lymphoma cells with 
adriamycin for 7 days. They reported that during resistance development, P-gp was 
not overexpressed in the initial stage, and these cells did not contribute to a stable cell 
line until P-gp was overexpressed (Lee et al, 1996b). Therefore it is believed that the 
adriamycin treated cells are in the initial stage of resistance development and they do 
not contribute to a resistant cell line. 
In another in vitro study on SaOS-2 cells conducted by Baldini and his co-workers 
(Baldini et al., 1992), it was shown that in the highly resistant variants of the SaOS-2 
cell line, the majority of cells showed resistance by A B A but only a few cells had 
increased expression ofP-gp. It is believed that the adriamycin resistant phenomenon 
is due to mechanisms other than P-gp overexpression. It may be the result of an 
elevated antioxidative enzymes activities or a mutation in the topoisomerase II gene. 
4.2.2. Proliferation Rate 
There is a significant reduction in the proliferation rate of cells cultured in the 
presence of adriamycin. The amount of thymidine taken up by SaOS-2 cells dropped 
to 49.02% of the original when 20ng/ml adriamycin was added into the culture 
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medium for 14 days and the amount became 20.52% of the original when the drug 
concentration was increased from 20ng/ml to 40ng/ml. One reason for this is the 
cytotoxicity of adriamycin. Most anticancer drugs can cause cell-cycle arrest, 
especially for those quinone-bearing molecules that can intercalate D N A (de Fraine et 
al, 1990). To escape from adriamycin injury, cells may stall in a dormant stage, so 
that they are less vulnerable to the drug. The proportion of cell stay in the dormant 
stage increased as drug concentration was increased. Therefore, the overall 
proliferation of the cell population decreased. 
Another reason for the retarded growth of adriamycin treated osteosarcoma cells may 
be the result of cell lipid peroxidation induced by the free radicals adriamycin 
generated (Doroshow, 1996). Upon reduction, anthracyclines can produce oxyradicals 
(Figure 4.1.) which can initiate peroxidation chain reaction on different biomolecules. 
Lipid peroxidation in mammalian cells would always give a complex pattern of 
aldehydes (Figure 4.2.). One ofthe major aldehydes formed is the 4-hydroxynonenal 
(HNE) (Zoliner et al., 1991). H N E is a toxic chemical although the sensitivity towards 
it strongly depended on the cell type. 
It is shown that in mammalian cells treated with a high concentration of HNE, acute 
toxic effects, such as severe damage and death within 1 hour, are observed. At a low 
concentration, H N E produces lethal effects upon prolonged incubation (Zoliner et al., 
1991). Besides, 4-hydroxyalkenals appear to possess the capacity to block cell 
proliferation at sub-lethal dose (Schauenstein, 1982; Hauptlorenz et al., 1985). 
Although the chemical reactions and molecular mechanisms involved are largely 
unknown, the lipophilicity of the aldehyde is an important parameter for HNE-
mediated growth inhibition (Kaneko et aI., 1988). 
In this study, as the adriamycin concentration was increased, the degree of lipid 
peroxidation in SaOS-2 cells increased. More H N E was produced and the inhibitory 
effect of this chemical became more prominent. The end result was an inhibited cell 
growth as revealed by the thymidine incorporation assay. 
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Figure 4.1. One-electron and two-electron reduction of adriamycin (Pratt et 
al., 1994). One-electron reduction produces semiquinone and two-
electron reduction yields dihydroquinone. Both products react 
rapidly with oxygen to give superoxide anions. 
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Figure 4.2. Peroxidation of unsaturated lipids yields a broad range of 
compounds. The two most important products are shown. 
Malondialdehyde (MDA) is used as an index of the degree 
of peroxidation and 4-hydroxyalkenals (4-HDA) is the 
substance that inhibits cell proliferation (R&D, 1996). 
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4.2.3. Antioxidative Enzymes Activities 
The effect of adriamycin on intracellular antioxidative enzymes activities has been 
studied by many investigators but there is still no consensus. Some authors reported 
that in a P-gp negative adriamycin-resistant human small cell lung cancer cell line, the 
levels of superoxide dismutase and GPx were not increased. Catalase activity was 
only one-third ofthat measured in sensitive cells (Meijer et aI., 1987). Another in vivo 
study showed that chemotherapy treated melanoma did not show any variation in the 
activities ofantioxidant enzymes (Crescimanno etal., 1991a). 
In this study, it was found that both catalase and GPx activities were lowered after 
treatment of adriamycin. Catalase activity dropped to 41.70% of the original when 
20ng/ml adriamycin was added into the culture medium and the figure became 
22.95% of the original when the drug concentration was increased to 40ngAnl. GPx 
activity also dropped to 60.46% and then 44.08% of the original. Similar observations 
were reported by Crescimanno et al. in 1991 (Crescimanno et aI., 1991b). They found 
that catalase and total GPx activities were reduced in resistant cells by 18% and 21%. 
Paranka & Dorr reported a 50% reduction in GPx activity in adriamycin-resistant 
cultured rat heart cells (Paranka & Dorr, 1994). 
Adriamycin mediates the formation of superoxide in microsomal incubations 
containing N A D P H (Handa & Sato，1975). Since catalase and GPx are inhibited by 
superoxide (Kono & Fridovich, 1982; Blum & Fridovich, 1985), it is believed that the 
decrease in the activities of the enzymes is due to the increased production of 
superoxide by adriamycin. These superoxide ions oxidize the active sites of the 
antioxidative enzymes, thus reducing their enzyme activity. However, since SOD is 
responsible for the removal of superoxide ions, an evaluation of SOD activity in the 
adriamycin treated cells is essential to confirm this hypothesis. 
Liebmann and his co-workers showed that a human breast adenocarcinoma cell line 
MCF-7^^ transfected with glutathione peroxidase gene GPX-I were not resistant to 
adriamycin despite a marked elevation in GPx activity (Liebmann et al., 1995). The 
protective effect of the antioxidative enzymes may be limited by the over-production 
of superoxide in this respect. Increased adriamycin tolerance may be effectuated more 
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efficiently by increased repair of free radical damage than by preventing this damage 
from occurring QVIeijer et al., 1990). 
Our data show that GPx and catalase activities are decreased in a similar pattern after 
adriamycin treatment. If the decrease in thymidine incorporation rate is taken into 
consideration, it can been seen that the metabolic activities of osteosarcoma cells in 
the presence of adriamycin may have decreased. This decrease is more or less 
proportional to the adriamycin concentration. W e may assume that the osteosarcoma 
cells are dying and therefore their anabolism has reduced. 
To sum up, it is believed that in this in vitro model, both P-gp overexpression and an 
enhanced rate of free radical removal do not protect osteosarcoma cells from the 
cytotoxicity of adriamycin. 
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5. CONCLUSION 
Our clinical study shows that pre-chemotherapy adriamycin binding assay can be 
employed to biopsy samples ofosteosarcoma patients before chemotherapy to screen 
out drug resistant tumours so that alternative treatment can be considered. Adriamycin 
may induce P-gp overexpression in osteosarcoma which confers M D R to the tumour 
cells, although not all M D R cases can be explained by P-gp overexpression. Elevation 
ofP-gp expression is due to an enhanced rate of m R N A translation and this increased 
P-gp expression helps the tumour cells to survive in the presence of cytotoxic drugs. 
P-gp expression and post-chemotherapy adriamycin sensitivity do not correlate with 
clinical outcome, and therefore cannot serve as a prognostic factor. 
In the cell line model, both the proliferation rate and antioxidative enzymes activities 
of osteosarcoma cells are lower after the treatment with low concentration of 
adriamycin. It is believed that free radicals are generated by adriamycin. These free 
radicals invoke lipid peroxidation and the lipid peroxidation product (4-
hydroxyalkenals) in tum inhibits cell growth. On the other hand, excess superoxide 
ions inhibit the activities of antioxidative enzymes. Moreover, P-gp is not induced 
during adriamycin treatment, although the cells are resistant as revealed by the ABA. 
Therefore it is believed that both P-gp and antioxidative enzymes do not protect 
osteosarcoma cells from the cytotoxicity of adriamycin. 
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6. FURTHER STUDY 
Osteosarcoma is rare compared to other types of cancer. This explains why there are 
relatively few samples in our study. More reliable conclusions can be drawn only if 
the sample pool is large. Future studies on osteosarcoma biology rely on the 
availability ofclinical specimens. These samples can be taken from other hospitals by 
collaboration or by accumulation over a longer period. Besides, a longer follow up 
period (e.g. over 2 years) is required for a more accurate hypothesis of the association 
between drug screening methods and clinical outcome ofpatients. 
As mentioned, early detection of M D R not only saves the cost of cancer treatment, 
but also reduces the side effects brought about by anticancer drugs. Traditional 
methods used to detect M D R , such as the A B A in our study, utilize the net 
accumulation of drug in tumour cells as an index of drug resistance. Since biopsy 
must be performed to take out part of the tumour for analysis, it is invasive and 
traumatic to the patient. A less invasive and traumatic method to assess drug response 
in osteosarcoma patients is to be established. 
Although there are many proposed mechanisms of action, how adriamycin mediates 
its cytotoxicity after entering tumour cells remains unknown. It has been shown that 
free radicals are generated by the drug (Doroshow, 1986), but it is unclear what will 
happen next. In this study, an evaluation of catalase and GPx has been done, but an 
association between these enzymes with adriamycin resistance has not been found. 
However, since catalase and GPx only contributes to a small part in the detoxification 
of R O S in cells, if the role of free radicals in adriamycin mediated osteosarcoma 
cytotoxicity is to be established, a more comprehensive assessment of the 
antioxidative status in adriamycin treated cells is needed. 
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8. APPENDK - SOLUTIONS PREPARATION 
Dulbecco's Modified Eagle's Medium (DMEM) 
D M E M powder (D-5523, Sigma, St. Louis) was dissolved in 900ml Milli-Q water. 
The original package was rinsed with a small amount ofMilli-Q water to remove all 
traces of powder. 3.7g NaHCO3 (31437，Merck, Darmstadt) was added to the 
medium. The pH of the medium was adjusted to 7.2 by l M HC1 and l M NaOH. 
Additional Milli-Q water was added to bring the solution to lL. The solution was 
sterilized immediately by vacuum filtration using a sterile 0.22^im membrane filter 
(Millipore, Massachusetts). Sterility of the medium was checked by incubating 5ml of 
the medium at 3TC ovemight. Sterile medium was stored at 4°C. 
Iscove's Modified Dulbecco's Medium (IMDM) 
EVlDM powder (I-7633, Sigma, St. Louis) was dissolved in 900ml Milli-Q water. The 
original package was rinsed with a small amount ofMilli-Q water to remove all traces 
of powder. 3.7g NaHCO3 (31437, Merck, Darmstadt) was added to the medium. The 
pH ofthe medium was adjusted to 7.2 by l M HC1 and lM NaOH. Additional Milli-Q 
water was added to bring the solution to lL. The solution was sterilized immediately 
by vacuum filtration using a sterile 0.22^im membrane filter (Millipore, 
Massachusetts). Sterility of the medium was checked by incubating 5ml of the 
medium at 37°C ovemight. Sterile medium was stored at 4°C. 
Phosphate Buffered Saline (PBS) 
lL 0.15M PBS was prepared by dissolving 8g NaCl (MC), 0.2g KC1 (4936, Merck, 
Darmstadt), 0.2g KH2PO4 (4873, Merck, Darmstadt) and 1.15g Na2HPO4.2H2O 
(6580, Merck, Darmstadt) in 950ml double distilled water. After titrating the solution 
with l M HC1 or l M N a O H to pH 7.4 at room temperature, the solution was diluted to 
lL with double distilled water. The solution was sterilized by autoclaving at 12TC, 
15 psi for 30 minutes. Sterile PBS was stored at 4°C. 
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Fetal Bovine Serum (FBS) 
FBS was purchased from Gibco B R L Products (16140-071, Gibco, Maryland). It had 
been heat inactivated by a thermostatic water bath at 56°C for 30 minutes. 50ml 
aliquots were dispensed aseptically into sterile bottles and stored at -20°C. 
Penicillin'Streptomycin-Neomycin (PSN) Antibiotic Mixture 
PSN antibiotic mixture liquid was purchased from Gibco B R L Products (15640-055, 
Gibco, Maryland). The solution contains 5mg of penicillin, 5mg of streptomycin and 
lOmg of neomycin in 0.85% saline. 10ml aliquots were dispensed aseptically into 
sterile bottles and stored at -20。C. 10% PSN was prepared by mixing 1ml PSN with 
9ml M D M . The solution was stored at -20°C. 
L-Glutandne Solution 
200mM stock L-glutamine solution was prepared by dissolving 0.2922g L-glutamine 
(G-3126, Sigma, St. Louis) in 10ml D M E M . The solution was immediately filtered 
through a sterile 0.22^im membrane filter (Millipore, Massachusetts). The sterile L-
glutamine solution was stored at -20°C. 
Mediumfor SaOS-2 Culture 
The medium was prepared by mixing 440ml D M E M , 50ml FBS, 5ml PSN and 5ml L-
glutamine solution aseptically. The resulting medium contains 10% FBS, 1% PSN and 
2 m M L-glutamine. 
MediumforKB-Vl Culture 
The medium was prepared by mixing 450ml D M E M and 50ml FBS aseptically. The 
resulting medium contains 10% FBS in D M E M . 
Trypsin-EDTA Solution 
Trypsin-EDTA solution (0.25% trypsin, l m M EDTA) was purchased from Gibco 
BRL Products (25200-056, Gibco, Maryland). The solution contains 2.5g/L oftrypsin 
(1:250) and 0.38g/L ofEDTA sodium salt in Hanks' Balanced Salt Solution, without 
Ca2+ and Mg�+. 10ml aliquots were dispensed aseptically into sterile bottles and stored 
at -20^C. 
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Trypan Blue Solution 
Prepared by dissolving 0.2g trypan blue crystal (T-0776, Sigma, St. Louis) in 50ml 
PBS. After filtration, the solution was stored at 4°C. 
Adriamycin Solution 
5ml Milli-Q water was injected into a vial containing lOmg adriamycin (Farmitalia 
Carlo Erba, Milano) to give a concentration of 2mg/ml. After reconstitution, the 
solution was drawn out and stored at 4。C. 
Vinblastine Solution 
10ml sterile normal saline was injected into a vial containing lOmg vinblastine 
sulphate OBli Lilly, Indiana) to give a concentration of lmg/ml. After reconstitution, 
the solution was drawn out and stored at 4。C. 
Collagenase Solution 
0.1% collagenase solution was prepared by dissolving 0.01g collagenase II (C-6885, 
Sigma, St. Louis) in 10ml EVDDM. The solution was filtered through a 0.22^im 
membrane for sterilization. The solution was stored at 4。C. 
Fluorescein Diacetate Solution 
Fluorescein diacetate solution was prepared by dissolving 0.01g fluorescein diacetate 
(F-7378, Sigma, St. Louis) in 20ml PBS. The solution was continuously stirred at 
60。C under dark condition for 10-15 minutes to facilitate solvation. After filtration 
through a 0.22p,m membrane filter, the solution was stored at -20°C in the dark. 
Neutral Buffered Formalin^ 10% 
Prepared by dissolving 4g NaH2PO4H2O (6346’ Merck, Darmstadt) and 6.5g 
Na2HPO4 (6586, Merck, Darmstadt) in 100ml formaldehyde. Distilled water was used 
to bring the final volume to lL. The pH ofthe solution was adjusted to 7.0 using lM 
HC1 and l M N a O H . 
Formic Acid/Formalin, 10% 
100ml formic acid (100264, Merck, Darmstadt) was mixed with 50ml formaldehyde 
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(4003, Merck, Darmstadt). Distilled water was used to bring the final volume to lL. 
Trypsin Solution 
Trypsin solution was prepared by dissolving 0.25mg trypsin (T-8253, Sigma, St. 
Louis) in 10ml PBS. The solution was stored at 4°C. 
Blocking Solution 
Blocking solution was prepared by dissolving O.lg bovine serum albumin (BSA) (A-
9647, Sigma, St. Louis) in 10ml PBS. The solution was stored at 4。C. 
Primary Antibody 
The primary antibody (SC-1517, Santa Cruz, California) is a goat polyclonal 
antibody. It was raised against a peptide corresponding to amino acids 1251-1269 
mapping at the carboxyl terminus of the multiple drug resistance protein 1 (Mdr-1) 
precursor of human origin. The working concentration of the primary antibody was 
1:100. It was stored at 4°C. 
Secondary Antibody 
The secondary antibody (A-3540, Sigma, St. Louis) was derived from rabbit. It was 
an anti-goat IgG-HRP conjugate. The antibody was diluted with PBS to 1:100 and 
stored at 4°C. 
Chromogen Substrate Solution 
lOmg diaminobenzidine hydrochloride (D-5637, Sigma, St. Louis) was dissolved in 
10ml PBS. 1ml aliquots were prepared and freezed at -20°C in the absence of light. 
The chromogen substrate solution is prepared immediately before use. Each aliquot 
was thawed and 7.5^ il of3% H2O2 solution was added as instructed by supplier. 
Thymidine Solution 
:5'-3H]Thymidine was purchased from Amersham Life Science (TRK328, 
Amersham, Uppsala) with a specific activity of 14.7CiAnmol. To prepare the 
20^iCiAnl working concentration, [5'-^]thymidine stock solution (lmCi/ml) was 
diluted by adding 20^ il of which into 980^ il D M E M . The solution was prepared 
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freshly each time of assay. 
Hepes with BSA Solution 
0.25mM Hepes with 2.5mgAnl B S A was prepared by dissolving 14.9mg Hepes 
powder (H-3375, Sigma, St. Louis) and 0.625g B S A (A-7888, Sigma, St. Louis) in 
250ml Milli-Q water. The solution was stored at 4。C. 
Scintillation Fluid 
One litre of scintillation fluid was prepared by dissolving 4g 2,5-diphenyloxazole (D-
4630, Sigma, St. Louis) and 0.2g l,4-bis[5-phenyl-2-oxazolyl]benzene (P-3754, 
Sigma, St. Louis) in a mixture of 330ml Triton X-100 and 670ml toluene. The 
mixture was stirred overnight and stored in a brown bottle at room temperature. 
Potassium Phosphate Buffer 
O.lM potassium phosphate buffer, pH 7.0, was prepared by diluting a mixture of 
6.15ml 0.5M KH2PO4 (4873, Merck, Darmstadt) solution and 3.85ml 0.5M K2HPO4 
(5104, Merck, Darmstadt) solution to 50ml. To prepare potassium phosphate buffer 
with l m M EDTA, 18.61mg E D T A disodium dihydrate (ED2SS, Sigma, St. Louis) 
was dissolved in the bufFer. 
Glutathione Reductase 
Commercial glutathione reductase (359960, Calbiochem, California) at a 
concentration of 600U/ml was diluted in potassium phosphate buffer with l m M 
E D T A to give 2.4U/ml activity. The enzyme solution was stored at 4°C. 
Glutathione, Reduced 
lOmM glutathione (G-6529，Sigma, St. Louis) was prepared by dissolving 15.37mg in 
5ml Milli-Q water. The solution was stored at 4°C. 
NADPHSolution 
Prepared by dissolving 6.25mg N A D P H 0sf-7505, Sigma, St. Louis) in 0.1% NaHCO3 
solution (31437, RDH, Seelze). The solution was prepared freshly each time. 
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Sodium Azide Solution 
l O m M sodium azide solution was prepared by dissolving 6.5mg NaN3 (6688, Merck, 
Darmstadt) in 10ml potassium phosphate buffer with l m M EDTA. The solution was 
stored at 4°C. 
Substrate Solution for Catalase 
30% H2O2 solution (18304, RDH, Seelze) was diluted to give l l m M in potassium 
phosphate buffer. The solution was stored at 4。C in the absence oflight. 
Substrate Solution for GPx 
30% H2O2 solution (18304, RDH, Seelze) was diluted to give 1.5mM in potassium 




Osteosarcoma is the most common primary malignant tumour of bone apart from 
myeloma. Many investigators are searching for prognostic factors to monitor the 
response of tumours to chemotherapy. Current studies focus on evaluating the 
reliability ofP-glycoprotein expression using immunohistochemistry data. However, 
its association with response to chemotherapy is controversial since P-glycoprotein 
immunohistochemistry may only help to detect multidrug resistance in highly 
resistant tumours. Baldini and his co-workers developed the adriamycin binding assay 
which is a clinical assay and enables detection of low levels of resistance in tumour 
cell cultures. In this study, the applicability ofP-glycoprotein immunohistochemistry 
and that ofthe adriamycin binding assay to predict tumour necrosis were compared. 
W e found that 46.15% of osteosarcoma samples studied had intrinsic adriamycin 
resistance as revealed by the adriamycin binding assay. However, P-glycoprotein 
expression was low in these samples. P-glycoprotein expression was elevated after 
chemotherapy, which may be the result of increased rate of synthesis. Pre-
chemotherapy adriamycin binding assay results correlate at a statistically significant 
value (p=0.042) with tumour necrosis. Post-chemotherapy adriamycin binding assay 
results and P-glycoprotein expression did not have a statistically significant 
correlation with tumour necrosis. Moreover, the correlation between adriamycin 
sensitivity and P-glycoprotein expression in our study was not statistically significant. 
In our osteosarcoma samples, P-glycoprotein expression is not the main reason for 
drug resistance as suggested by the adriamycin binding assay. Alternative mechanisms 
for drug resistance have been demonstrated. Adriamycin is known to impose growth 
inhibition on cancer cells. However, its effect on the activities of antioxidative 
enzymes is controversial. W e postulate that intracellular antioxidants might play a role 
in modulating drug response in osteosarcoma cells. Therefore, we extended our study 
using an in vitro model to investigate the effect of adriamycin on the proliferation rate 
and the activities of two critical antioxidative enzymes, catalase and glutathione 
peroxidase, in an osteosarcoma cell line. In addition, the adriamycin binding assay 
and P-glycoprotein immunohistochemistry were used to monitor the change of drug 
sensitivity during drug treatment in this model. 
Our in vitro study showed that after adriamycin treatment up to 40ng/ml, the 
osteosarcoma cells developed adriamycin resistance, yet P-glycoprotein expression 
was not induced. The proliferation rate and the activities of antioxidative enzymes 
were all suppressed after incubating the cells with sub-concentration of adriamycin. 
The decrease in proliferation rate and antioxidative enzymes activities was postulated 
to be due to an inhibition by excess superoxide ions generated by adriamycin through 
quinone reduction. 
In this study, we have clearly demonstrated that pre-chemotherapy adriamycin binding 
assay is critical for screening out patients who are intrinsically drug resistant. W e also 
find that P-glycoprotein overexpression and enhanced activities of antioxidative 
enzymes may not be the reasons for adriamycin resistance. Further studies on other 
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